Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 6/20 | 0.41 |
| ▸ | KMO | O15229 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 5/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | HTR1B | P28222 | 1/20 | 0.39 |
| ▸ | HTR1F | P30939 | 1/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.38 |
| ▸ | PDE9A | O76083 | 1/20 | 0.38 |
| ▸ | SCD | O00767 | 3/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.36 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19698021 | 0.98 | PIK3CD (0.41) | PIK3CDKMOHTR7HTR6HTR1A | |
| SCHEMBL17677989 | 0.97 | PIK3CD (0.41) | PIK3CDKMOHTR7HTR6HTR1A | |
| SCHEMBL16595822 | 0.93 | KMO (0.43) | PIK3CDKMOHTR7HTR1AHTR1B | |
| SCHEMBL31104405 | 0.93 | KMO (0.43) | PIK3CDKMOHTR7HTR1AHTR1B | |
| SCHEMBL25045382 | 0.87 | HTR7 (0.39) | PIK3CDHTR7PDE9ASCD | |
| SCHEMBL19279681 | 0.87 | PIK3CD (0.46) | PIK3CDKMOHTR1AHTR1BHTR1F | |
| SCHEMBL31757809 | 0.86 | MEN1 (0.42) | PIK3CDKMOHTR1AHTR1BHTR1F | |
| SCHEMBL19279630 | 0.86 | PIK3CD (0.55) | PIK3CDKMO | |
| SCHEMBL19279654 | 0.86 | PIK3CD (0.39) | PIK3CDKMOHTR1AHTR1BHTR1F | |
| SCHEMBL19703386 | 0.86 | MEN1 (0.42) | PIK3CDKMOHTR1AHTR1BHTR1F |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7781460-B2 | Substituted indazoles as inhibitors of phosphodiesterase type-IV | RANBAXY LABORATORIES LIMITED (IN) | 2010-08-24 | — | — | US | disclosed |
| US-20080312285-A1 | Substituted Indazoles as Inhibitors of Phosphodiesterase Type-Iv | RANBAXY LABORATORIES LIMITED (IN) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312285-A1 | Substituted Indazoles as Inhibitors of Phosphodiesterase Type-Iv | PDE3B, PDE3A, PDE7A | PIK3CD 159/4885KMO 740/4885HTR7 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.